References
Brock N, Stekar J, Pohl U, Niemeyer U, Scheffler G (1979) Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. ArzneimForsch 29 (I): 659–661
Link H, Meyer P, Neef V, Niethammer D, Wilms K (1980) Uromitexan bei hochdosierter Endoxan-Therapie im Rahmen der Knochenmarktransplantation. In: Beiträge zur Onkologie, Vol 5. Karger, Basel München Paris London New York Sydney, S 111–115
Pohl J (1980) Toxikologie, Pharmakokinetik und Interaktion von Uromitexan. In: Beiträge zur Onkologie, Vol. 5. Karger, Basel München Paris London New York Sydney, S 12–20
Scheef W, Klein HO, Brock N, Burkert H, Günther U, Hoefer-Janker H, Mitrenga D, Schnitker J, Voigtmann R (1979) Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: Preliminary results. Cancer Treat Rep 63: 501–505
Storb R, Thomas ED, Weiden PL, Buckner CD, Clift RA, Fefer A, Fernando LP, Giblett ER, Goodell BW, Johnson FL, Lerner KG, Neiman PE, Sanders JE (1976) Aplastic anaemia treated by allogeneic bone marrow transplantation: A Report on 49 new cases from Seattle. Blood 48: 817–841
Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PF, Lerner KG, Glucksberg H, Buckner CD (1975) Bone Marrow Transplantation. N Engl J Med 292: 832–843, 895–902
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Link, H., Neef, V., Niethammer, D. et al. Prophylaxis of haemorrhagic cystitis due to cyclophosphamide-conditioning for bone marrow transplantation. Blut 43, 329–330 (1981). https://doi.org/10.1007/BF00320957
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320957